Who
Alicia Secor
Director
Company insider
Files Form 4 as: Director, Zevra Therapeutics; Director, G1 Therapeutics; Director, Orchard Therapeutics; Director, Gw Pharmaceuticals; President and CEO, Juniper Pharmaceuticals; Chief Commercial Officer, Larimar Therapeutics; SVP, Chief Operating Officer, Synageva Biopharma.
In numbers
- Trades disclosed
- 65
- Buys
- 2
- Sells
- 4
- Bought
- $109K
- Sold
- $1.1M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 19 Sep 2013
- Last trade
- 4 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Dec 2025filed 9 Dec 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeutics | SEC FORM 4 Code D | —20,000 | filing |
| 18 Sep 2024filed 18 Sep 2024 | G1 Therapeutics | SEC FORM 4 Code U | —10,000 | filing |
| 13 Jun 2024filed 14 Jun 2024 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Jan 2024filed 24 Jan 2024 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code D | —46,000 at $0.00 | filing |
| 24 Jan 2024filed 24 Jan 2024 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code D | —105,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | G1 Therapeutics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 17 Jun 2021filed 21 Jun 2021 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code A | —52,320 at $0.00 | filing |
| 16 Jun 2021filed 17 Jun 2021 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.